Engineering Magnetosomes for High-Performance Cancer Vaccination.

Feng Li,Weidong Nie,Fan Zhang,Guihong Lu,Chengliang Lv,Yanlin Lv,Weier Bao,Lijun Zhang,Shuang Wang,Xiaoyong Gao,Wei Wei,Hai-Yan Xie
DOI: https://doi.org/10.1021/acscentsci.9b00060
IF: 18.2
2019-01-01
ACS Central Science
Abstract:A novel cancer vaccine is developed by using Fe3O4 magnetic nanoclusters (MNCs) as the core and cancer cell membranes decorated with anti-CD205 as the cloak. Because of the superparamagnetism and magnetization of MNCs, it is first achieved for the magnetic retention of vaccine in the lymph nodes with a magnetic resonance imaging (MRI) guide, which opened the time window for antigen uptake by dendritic cells (DCs). Meanwhile, the camouflaged cancer cell membranes serve as a reservoir of various antigens, enabling subsequent multiantigenic response. Additionally, the decorated anti-CD205 direct more vaccine into CD8+ DCs, facilitating the major histocompatibility complex (MHC) I cross-presentation. These unique advantages together lead to a great proliferation of T cells with superior clonal diversity and cytotoxic activity. As a result, potent prophylactic and therapeutic effects with few abnormalities are observed on five different tumor models. Therefore, such a cancer-derived magnetosome with the integration of various recent nanotechnologies successfully demonstrates its promise for safe and high-performance cancer vaccination.
What problem does this paper attempt to address?